Inside the first-of-its-kind Enable Injections enFuse drug delivery wearable

Enable Injections' enFuse on-body injector (OBI) platform achieved its second FDA approval in July 2026 when Sanofi received clearance for an anticancer treatment using the device. The enFuse system previously secured its first combination product approval in 2023 for paroxysmal nocturnal hemoglobinuria. The platform represents a first-of-its-kind wearable drug delivery technology in the oncology space.